Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530907 · ClinicalTrials.gov registry record · Phase 1
Valproic Acid and Bevacizumab in Patients With Advanced Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT00530907: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00530907 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 71 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00530907, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of bevacizumab in combination with valproic acid that can be given to patients with advanced cancer that has not responded to standard treatment or where there is no standard treatment for the disease. The safety of this drug combination will also be studied.
Interventions
- DRUG Bevacizumab
- DRUG Valproic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00530907
The ClinicalTrials.gov registry entry for NCT00530907 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00530907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00530907 about?
NCT00530907 is a clinical study titled "Valproic Acid and Bevacizumab in Patients With Advanced Cancer". The goal of this clinical research study is to find the highest tolerable dose of bevacizumab in combination with valproic acid that can be given to patients with advanced cancer that has not responded to standard treatment or where there is no standard treatment for the disease. The safety of this ...
What is the current status of trial NCT00530907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2007-06. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00530907?
The interventions under investigation include: Bevacizumab (DRUG), Valproic Acid (DRUG).
Who is sponsoring clinical trial NCT00530907?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.